A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer

Clinical Cancer Research

Volumn 9, Issue 16, 2003, Pages 5922-5928

  Wolff, Antonio C ^a   Armstrong, Deborah K ^a   Fetting, John H ^a   Carducci, M Katherine ^a   Riley, Carol D ^a   Bender, John F ^b,c   Casero, Robert A ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b 2Parke Davis Pharmaceutical Research   (United States)

^c Favrille Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; N1,N11 DIETHYLNORSPERMINE; ORNITHINE DECARBOXYLASE; POLYAMINE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; ATAXIA; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DRUG EFFECT; DRUG EFFICACY; DYSARTHRIA; DYSPHAGIA; EDEMA; FEMALE; FLUSHING; GROWTH INHIBITION; HEADACHE; HUMAN; HYPOMAGNESEMIA; NAUSEA; NEUROTOXICITY; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECEPTOR DOWN REGULATION; SIDE EFFECT; SKIN TOXICITY; SLURRED SPEECH; SOMNOLENCE; THROMBOCYTOPENIA; TINNITUS; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; SPERMINE; SURVIVAL RATE;

EID: 0346734280     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Russell, D. H., Levy, C. C., Schimpff, S. C., and Hawk, I. A. Urinary polyamines in cancer patients. Cancer Res., 31: 1555-1558, 1971.
2. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res., 48: 759-774, 1988.
3. Wallace, H. M., and Fraser, A. V. Polyamine analogues as anticancer drugs. Biochem. Soc. Trans., 31: 393-396, 2003.
4. Pepin, J., Milord, F., Guern, C., and Schechter, P. J. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet, 2: 1431-1433, 1987.
5. Meyskens, F. L., Jr., and Gerner, E. W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res., 5: 945-951, 1999.
6. Manni, A., Mauger, D., Gimotty, P., and Badger, B. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin. Cancer Res., 2: 1901-1906, 1996.
7. O'shaughnessy, J. A., Demers, L. M., Jones, S. E., Arseneau, J., Khandelwal, P., George, T., Gersh, R., Mauger, D., and Manni, A. α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin. Cancer Res., 5: 3438-3444, 1999.
8. Levin, V. A., Hess, K. R., Choucair, A., Flynn, P. J., Jaeckle, K. A., Kyritsis, A. P., Yung, W. K., Prados, M. D., Bruner, J. M., Ictech, S., Gleason, M. J., and Kim, H. W. Phase III randomized study of postradiotherapy chemotherapy with combination α-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res., 9: 981-990, 2003.
9. Wang, Y., Devereux, W., Woster, P. M., Stewart, T. M., Hacker, A., and Casero, R. A., Jr. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res., 61: 5370-5373, 2001.
10. Casero, R. A., Wang, Y., Stewart, T. M., Devereux, W., Hacker, A., Smith, R., and Woster, P. M. The role of polyamine catabolism in anti-tumour drug response. Biochem. Soc. Trans., 31: 361-365, 2003.
11. Casero, R. A., Jr., Celano, P., Ervin, S. J., Porter, C. W., Bergeron, R. J., and Libby, P. R. Differential induction of spermidine/spermine N1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Cancer Res., 49: 3829-3833, 1989.
12. Casero, R. A., Jr., Ervin, S. J., Celano, P., Baylin, S. B., and Bergeron, R. J. Differential response to treatment with the bis(ethyl)- polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture. Cancer Res., 49: 639-643, 1989.
13. Porter, C. W., Ganis, B., Libby, P. R., and Bergeron, R. J. Correlations between polyamine analogue-induced increases in spermidine/ spermine N1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res., 51: 3715-3720, 1991.
14. Bernacki, R. J., Bergeron, R. J., and Porter, C. W. Antitumor activity of N, N’-bis(ethyl)spermine homologues against human MALME-3 melanoma xenografts. Cancer Res., 52: 2424-2430, 1992.
15. Porter, C. W., Bernacki, R. J., Miller, J., and Bergeron, R. J. Antitumor activity of N1, N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Cancer Res., 53: 581-586, 1993.
16. Bernacki, R. J., Oberman, E. J., Seweryniak, K. E., Atwood, A., Bergeron, R. J., and Porter, C. W. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin. Cancer Res., 1: 847-857, 1995.
17. Davidson, N. E., Mank, A. R., Prestigiacomo, L. J., Bergeron, R. J., and Casero, R. A., Jr. Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. Cancer Res., 53: 2071-2075, 1993.
18. Davidson, N. E., Hahm, H. A., McCloskey, D. E., Woster, P. M., and Casero, R. A., Jr. Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr. Relat. Cancer, 6: 69-73, 1999.
19. Creaven, P. J., Perez, R., Pendyala, L., Meropol, N. J., Loewen, G., Levine, E., Berghorn, E., and Raghavan, D. Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. Invest. New Drugs, 15: 227-234, 1997.
20. Streiff, R. R., and Bender, J. F. Phase 1 study of N1–N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest. New Drugs, 19: 29-39, 2001.
21. Hahm, H. A., Ettinger, D. S., Bowling, K., Hoker, B., Chen, T. L., Zabelina, Y., and Casero, R. A., Jr. Phase I study of N(1),N(11)- diethylnorspermine in patients with non-small cell lung cancer. Clin. Cancer Res., 8: 684-690, 2002.
22. Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., and Wood, W. C. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol., 21: 588-592, 2003.
23. Thall, P. F., Simon, R., and Ellenberg, S. S. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics, 45: 537-547, 1989.
24. Siu, L. L., Rowinsky, E. K., Hammond, L. A., Weiss, G. R., Hidalgo, M., Clark, G. M., Moczygemba, J., Choi, L., Linnartz, R., Barbet, N. C., Sklenar, I. T., Capdeville, R., Gan, G., Porter, C. W., Von Hoff, D. D., and Eckhardt, S. G. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies. Clin. Cancer Res., 8: 2157-2166, 2002.
25. Levin, V. A., Prados, M. D., Yung, W. K., Gleason, M. J., Ictech, S., and Malec, M. Treatment of recurrent gliomas with eflornithine. J. Natl. Cancer Inst., 84: 1432-1437, 1992.
26. Seidenfeld, J., Gray, J. W., and Marton, L. J. Depletion of 9L rat brain tumor cell polyamine content by treatment with D,L-α-difluoromethylornithine inhibits proliferation and the G1 to S transition. Exp. Cell Res., 131: 209-216, 1981.
27. McCloskey, D. E., Casero, R. A., Jr., Woster, P. M., and Davidson, N. E. Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res., 55: 3233-3236, 1995.
28. Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H. U., Brown, C. S., and Griffin, T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol., 17: 485-493, 1999.
29. Costanza, M. E., Weiss, R. B., Henderson, I. C., Norton, L., Berry, D. A., Cirrincione, C., Winer, E., Wood, W. C., Frei, E., III, McIntyre, O. R., and Schilsky, R. L. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642. J. Clin. Oncol., 17: 1397-1406, 1999.
30. Hahm, H. A., Dunn, V. R., Butash, K. A., Deveraux, W. L., Woster, P. M., Casero, R. A., Jr., and Davidson, N. E. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin. Cancer Res., 7: 391-399, 2001.
31. Valasinas, A., Sarkar, A., Reddy, V. K., Marton, L. J., Basu, H. S., and Frydman, B. Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4–4-4): synthesis and growth inhibitory effects on human prostate cancer cells. J. Med. Chem., 44: 390-403, 2001.
32. Bacchi, C. J., Weiss, L. M., Lane, S., Frydman, B., Valasinas, A., Reddy, V., Sun, J. S., Marton, L. J., Khan, I. A., Moretto, M., Yarlett, N., and Wittner, M. Novel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infection. Antimicrob. Agents Chemother., 46: 55-61, 2002.
33. Huang, Y., Hager, E. R., Phillips, D. L., Dunn, V. R., Hacker, A., Frydman, B., Kink, J. A., Valasinas, A. L., Reddy, V. K., Marton, L. J., Casero, R. A., Jr., and Davidson, N. E. A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clin. Cancer Res., 9: 2769-2777, 2003.